Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. METHODS: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores). RESULTS: Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events. CONCLUSIONS: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subset of those suffering from Major Depressive Disorder (MDD) achieve remission with antidepressant medication (ADM)1.”
From The relationship between resting-state functional connectivity, antidepressant discontinuation and depression relapse (2020) · cites this paper as [1]
In the citing paper
“about onethird receive no benefit from two or more pharmacologic treatments (Rush et al., 2006;Trivedi et al., 2006).”
From Neurocognitive effects of theta burst stimulation for treatment-resistant depression in adults: A systematic review and recommendations for future research (2025) · cites this paper as Rush et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationCUMULATIVE ILLNESS RATING SCALE
LINN, B. S., LINN, M. W., & GUREL, L. (1968) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1968.tb02103.x · Cited by 2,304
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Self-citationAgency for Health Care Policy and Research
Eisenberg, J. M. (1999) · Medical Care · doi:10.1097/00005650-199903000-00001 · Cited by 1,369
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Self-citationMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Self-citation
Research works printed but not linked: 4
- Agency for Health Care Policy and Research. Depression in primary care. Vol. 2. Treatment of major depression. Rockville, Md.: Department of Health and Human Services, 1993. (AHCPR publication no. 93-0551.)
- Fava M, 2000, J Clin Psychiatry, 61, 10
- Joffe RT, 1996, J Clin Psychiatry, 57, 114
- Fava M, 2003, Ann Clin Psychiatry, 15, 17, 10.3109/10401230309085666 · doi:10.3109/10401230309085666 · Paper page
Cited by
Items 301–400 of 999
Baghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Goodwin, G. M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Malt, U. F., Stein, D. J., et al. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0259-6 · Cited by 54
“In detail, approximately 25% of patients who did not respond to citalopram can benefit from switching either to sertraline, bupropion, or venlafaxine [379]; but the mean daily dose of venlafaxine (190 mg) used is below the dose generally recognized as possessing noradrenergic effects (225 mg/d) [71, 121], while during…”
BackgroundKobak, K. A., Williams, J. B. W., Jeglic, E., Salvucci, D., & Sharp, I. R. (2008) · Depression and Anxiety · doi:10.1002/da.20392 · Cited by 50
McClintock, S. M., Martin, D. M., Lisanby, S. H., Alonzo, A., McDonald, W. M., Aaronson, S. T., Husain, M. M., O’Reardon, J. P., Weickert, C. S., Mohan, A., et al. (2020) · Depression and Anxiety · doi:10.1002/da.22988 · Cited by 54
“…given limited response and remission rates and possible adverse treatment‐ associated side effects, the neuropsychiatric field is in need of more effective antidepressant therapies (Collins, Patel, Joestl, March, & Insel, 2011; McClintock et al., 2018; Rush et al., 2006; Sachs et al., 2007).”
BackgroundHormone treatment of depression
Joffe, R. T. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.1/rjoffe · Cited by 50
Eche, J., Mondino, M., Haesebaert, F., Saoud, M., Poulet, E., & Brunelin, J. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00013 · Cited by 48
Wang, Y., Li, N., Yang, L., Song, M., Shi, L., Chen, W., Li, S., Wang, X., & Lü, L. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.04.005 · Cited by 52
Olfson, M., Amos, T. B., Benson, C., McRae, J., & Marcus, S. C. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.3.226 · Cited by 48
Solomon, D., Adams, J., & Graves, N. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.11.064 · Cited by 54
“(Rush et al., 2006)”
MethodSouery, D., Serretti, A., Calati, R., Oswald, P., Massat, I., Konstantinidis, A., Linotte, S., Kasper, S., Montgomery, S., Zohar, J., et al. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.590225 · Cited by 49
Ogawa, S., & Kunugi, H. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150612225212 · Cited by 51
“Unfortunately, however, a substantial proportion of patients with MDD failed to respond to first-line therapeutic drugs such as selective serotonin reuptake inhibitors (SSRI) and serotoninnorepinephrine reuptake inhibitors [3].”
Padberg, F., Kumpf, U., Mansmann, U., Palm, U., Plewnia, C., Langguth, B., Zwanzger, P., Fallgatter, A. J., Nolden, J., Burger, M., et al. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0769-y · Cited by 57
“A 15–25% of patients manifest a chronic, treatment-resistant course of illness [3] resulting in a need for additional treatment options [4, 5].”
BackgroundGut Microbiota and Pathophysiology of Depressive Disorder
Kunugi, H. (2021) · Annals of Nutrition and Metabolism · doi:10.1159/000518274 · Cited by 55
Nutt, D. J., Baldwin, D. S., Clayton, A. H., Elgie, R., Lecrubier, Y., Montejo, A. L., Papakostas, G. I., Souery, D., Trivedi, M. H., & Tylee, A. T. (2006) · PubMed · Cited by 52
Self-citationA Critical Overview of the Pharmacologic Management of Treatment-Resistant Depression
Nierenberg, A. A., Katz, J., & Fava, M. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.01.001 · Cited by 52
Self-citationAlbert, P., & Fiori, L. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660740 · Cited by 46
“For example, in the STAR*D studies, only about 50% of patients responded to the initial SSRI treatment, which achieved a remission rate of only 30% [23-28].”
BackgroundThe Emerging Use of Technology for the Treatment of Depression and Other Neuropsychiatric Disorders
Howland, R. H., Shutt, L. S., Berman, S. R., Spotts, C. R., & Denko, T. (2011) · Annals of Clinical Psychiatry · doi:10.1177/104012371102300108 · Cited by 46
Clinical trials: Bridging the gap between efficacy and effectiveness
Depp, C., & Lebowitz, B. D. (2007) · International Review of Psychiatry · doi:10.1080/09540260701563320 · Cited by 46
“…in peer-reviewed journals (Rush et al., 2004; Sachs et al., 2003; Schneider et al., 2003; Stroup et al., 2003) and the initial findings have been published in major, high impact journals (Lieberman et al., 2005; Nierenberg et al., 2006; Perlis et al., 2006; Rush et al., 2006; Trivedi et al., 2006).”
BackgroundThe Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder
Moreira, R. (2011) · Clinical Drug Investigation · doi:10.2165/1159616-s0-000000000-00000 · Cited by 55
“Switching to bupropion SR after failure of citalopram therapy for MDD (lack of remission or intolerance to citalopram) was as efficacious as switching to the SSRI sertraline or the SNRI venlafaxine XR in terms of HAM-D-17 remission rates and the 16-item Quick inventory of depressive symptomatology–self-report (QIDS-SR…”
Omega-3 Fatty Acids for Depression in Multiple Sclerosis: A Randomized Pilot Study
Shinto, L., Marracci, G., Mohr, D. C., Bumgarner, L., Murchison, C., Senders, A., & Bourdette, D. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147195 · Cited by 46
Baune, B. T. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_19 · Cited by 49
“Additionally, more than 50% of patients on antidepressants will not achieve remission following initial treatment [4], and nearly one-third will not achieve remission following several treatment steps [5, 6].”
BackgroundInfluentialRedefining Affective Disorders: Relevance for Drug Development
Targum, S. D., Pollack, M. H., & Fava, M. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1527-3458.2008.00038.x · Cited by 45
Papakostas, G. I., Cooper-Kazaz, R., Appelhof, B. C., Posternak, M. A., Johnson, D. P., Klibanski, A., Lerer, B., & Fava, M. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328314dfaf · Cited by 45
“…is becoming increasingly clear that contemporary antidepressants, when used as monotherapy for MDD, demonstrate, at best, modest overall efficacy (Fava et al., 2006; McGrath et al., 2006; Rush et al., 2006; Trivedi et al., 2006) as well as a relatively slow onset of action (Quitkin et al., 2003).”
BackgroundPatient-reported outcomes before and after treatment of major depressive disorder
IsHak, W. W., Mirocha, J., Pi, S., Tobia, G., Becker, B., Peselow, E. D., & Cohen, R. M. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.2/rcohen · Cited by 45
Kim, N., Cho, S., Kim, H.-Y., Kim, S. H., Lee, H. J., Park, C. H. K., Rhee, S. J., Kim, D.-W., Yang, B. R., Choi, S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221552 · Cited by 48
Gartlehner, G., Dobrescu, A., Chapman, A., Toromanova, A., Emprechtinger, R., Persad, E., Affengruber, L., Pieh, C., Klerings, I., & Wagner, G. (2023) · Annals of Internal Medicine · doi:10.7326/m22-1845 · Cited by 43
Eisendrath, S. J., Gillung, E. P., Delucchi, K. L., Chartier, M., Mathalon, D. H., Sullivan, J. C., Segal, Z. V., & Feldman, M. D. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-95 · Cited by 43
Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
de Sousa, R. T., V. Zanetti, M., R. Brunoni, A., & Machado-Vieira, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630173522 · Cited by 43
Genomic prediction of depression risk and resilience under stress
Fang, Y., Scott, L., Song, P., Burmeister, M., & Sen, S. (2019) · Nature Human Behaviour · doi:10.1038/s41562-019-0759-3 · Cited by 43
Bunka, M., Wong, G. W. K., Kim, D., Edwards, L., Austin, J., Doyle‐Waters, M. M., Gaedigk, A., & Bryan, S. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115102 · Cited by 50
Piser, T. M. (2010) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2010.02.006 · Cited by 50
“Even when effective, current anti-depressant treatments were commonly followed by relapse within 4–10 months (Rush et al., 2006a,b).”
BackgroundDeep brain stimulation in the treatment of depression: DBS for depression
Blomstedt, P. C., Sjöberg, R. L., Hansson, M., Bodlund, O., & Hariz, M. I. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01625.x · Cited by 48
Ang, Y.-S., Kaiser, R., Deckersbach, T., Almeida, J., Phillips, M. L., Chase, H. W., Webb, C. A., Parsey, R., Fava, M., McGrath, P., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.04.009 · Cited by 43
Self-citationDolder, C. R., Nelson, M., & Stump, A. (2010) · Drugs & Aging · doi:10.2165/11537140-000000000-00000 · Cited by 48
Demitrack, M. A., & E.Thase, M. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4312 · Cited by 43
Self-citationClinical Update on Nursing Home Medicine: 2009
Messinger‐Rapport, B. J., Thomas, D. R., Gammack, J. K., & Morley, J. E. (2009) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2009.08.001 · Cited by 53
Rush, A. J., Trivedi, M. H., Stewart, J. W., Nierenberg, A. A., Fava, M., Kurian, B. T., Warden, D., Morris, D. W., Luther, J. F., Husain, M. M., et al. (2012) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.10.4.492 · Cited by 42
Self-citationMoreines, J. L., McClintock, S. M., Kelley, M. E., Holtzheimer, P. E., & Mayberg, H. S. (2014) · Depression and Anxiety · doi:10.1002/da.22263 · Cited by 42
“[1–5] As such, treatmentresistant depression (TRD) is a pervasive and debilitating disorder resulting in significant morbidity and mortality.”
BackgroundPharmacological management of unipolar depression
Malhi, G. S., Hitching, R., Berk, M., Boyce, P., Porter, R., & Fritz, K. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12122 · Cited by 42
Herbert, D., Neves-Pereira, M., Baidya, R., Cheema, S. Y., Groleau, S. E., Shahmirian, A., Tiwari, A. K., Zai, C. C. H., King, N. A., Müller, D. J., et al. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.09.002 · Cited by 42
“Rush and colleagues observed that up to 30% of depression patients experienced worsened symptoms or adverse events, causing them to discontinue their medication, or have an unwillingness to consider alternative drug treatment options (Rush et al., 2006a, 2006b).”
BackgroundRemission of maternal depression and child symptoms among single mothers: A STAR*D-Child report
Talati, A., WICKRAMARATNE, P. J., Pilowsky, D. J., Alpert, J. E., Cerda, G., Garber, J., Hughes, C. W., King, C. A., Malloy, E., Sood, A. B., et al. (2007) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-007-0262-4 · Cited by 45
“Methods Study design STAR*D Child was an ancillary study based on STAR*D, a multi-site trial detailed elsewhere [17,33,35,38].”
MethodSelf-citationJanicak, P. G., Dunner, D. L., Aaronson, S. T., Carpenter, L. L., Boyadjis, T. A., Brock, D. G., Cook, I. A., Lanocha, K., Solvason, H. B., Bonneh-Barkay, D., et al. (2013) · CNS Spectrums · doi:10.1017/s1092852913000357 · Cited by 42
Bradley, A. J., & Lenox‐Smith, A. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113494937 · Cited by 47
“Patients who failed to achieve remission (in this case defined as a score of ≥5 on the 16-item Quick Inventory of Depressive SymptomatologyClinician Rated (QIDS-C-16) or were intolerant of citalopram were eligible to continue to step 2 of the study, where they could choose from several treatment pathways including a s…”
BackgroundMethodInfluentialGoldberg, J. F., Freeman, M. P., Balon, R., Citrome, L., Thase, M. E., Kane, J. M., & Fava, M. (2015) · Depression and Anxiety · doi:10.1002/da.22378 · Cited by 40
Self-citationOlgiati, P., Bajo, E., Bigelli, M., Ronchi, D. D., & Serretti, A. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.08.013 · Cited by 44
“Although this solution was successfully used to improve response in SSRI-resistant depression (Trivedi et al., 2006), its results are comparable to switching to bupropion after the failure of SSRI treatment (Rush et al., 2006b).”
InfluentialDunlop, B. W., Parikh, S. V., Rothschild, A. J., Thase, M. E., DeBattista, C., Conway, C. R., Forester, B. P., Mondimore, F. M., Shelton, R. C., Macaluso, M., et al. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2410-2 · Cited by 43
Self-citationRazza, L. B., dos Santos, L. A., Borrione, L., Bellini, H., Castelo-Branco, L. E. C., Cretaz, E., Duarte, D. G. G., Ferrão, Y. A., Galhardoni, R., Quevedo, J., et al. (2021) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-1169 · Cited by 47
Identification of bipolar disorder in women with postpartum depression
Sharma, V., & Khan, M. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00809.x · Cited by 44
Bupropion in the Treatment of Outpatients with Asthma and Major Depressive Disorder
Brown, E. S., Vornik, L. A., Khan, D. A., & Rush, A. J. (2007) · The International Journal of Psychiatry in Medicine · doi:10.2190/d235-2285-2121-6724 · Cited by 40
Self-citationThe STAR*D Study: A Four-Course Meal That Leaves Us Wanting More
Nelson, J. C. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1864 · Cited by 43
Amsterdam, J. D., Williams, D., Michelson, D., Adler, L. A., Dunner, D. L., Nierenberg, A. A., Reimherr, F. W., & Schatzberg, A. F. (2009) · Neuropsychobiology · doi:10.1159/000226611 · Cited by 39
Self-citationStimulant Dosing for Children With ADHD: A Medical Claims Analysis
Olfson, M., Marcus, S., & Wan, G. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31818b1c8f · Cited by 39
Bschor, T. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.137 · Cited by 39
Gudayol‐Ferré, E., Herrera‐Guzmán, I., Camarena, B., Cortés‐Penagos, C., Herrera‐Abarca, J. E., Martínez‐Medina, P., la Cruz, D. C.-D., Hernández, S., Genis, A. D., Carrillo-Guerrero, M. Y., et al. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.002 · Cited by 42
Nakajima, S., Uchida, H., Suzuki, T., Watanabe, K., Hirano, J., Yagihashi, T., Takeuchi, H., Abe, T., Kashima, H., & Mimura, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.08.008 · Cited by 40
Thomas, L., Abel, A., Ridgway, N., Peters, T., Kessler, D. S., Hollinghurst, S. P., Turner, K. M., Garland, A., Jerrom, B., Morrison, J., et al. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.10.016 · Cited by 38
Reti, I. M., Schwarz, N., Bower, A., Tibbs, M., & Rao, V. (2015) · Brain Injury · doi:10.3109/02699052.2015.1009168 · Cited by 38
“Two recent observational studies show response rates of 50% [33, 34], which compares favourably with STAR-D outcomes for antidepressant medication [35].”
ResultFranco-Chaves, J. A., Mateus, C. F., Luckenbaugh, D. A., Martinez, P. E., Mallinger, A. G., & Zarate, C. A. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.02.003 · Cited by 38
“Some evidence suggests that newer antidepressants acting on two or more amine neurotransmitters may produce higher rates of remission when first-line agents that affect a single neurotransmitter have failed, but the remission rate remains below 40% (Baldomero et al., 2005; Lenox-Smith and Jiang, 2008; Papakostas et al…”
BackgroundWeikum, W., Mayes, L. C., GRUNAU, R. E., Brain, U. M., & Oberlander, T. F. (2013) · Infant Behavior and Development · doi:10.1016/j.infbeh.2013.04.001 · Cited by 41
Toward a very brief quality of life enjoyment and Satisfaction Questionnaire
Rush, A. J., South, C. C., Jha, M. K., Grannemann, B. D., & Trivedi, M. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.08.052 · Cited by 39
Self-citationA connectomic analysis of deep brain stimulation for treatment-resistant depression
Zhu, Z., Hubbard, E., Guo, X., Barbosa, D. A. N., Popal, A. M., Cai, C., Jiang, H., Zheng, Z., Lin, J., Gao, W., et al. (2021) · Brain Stimulation · doi:10.1016/j.brs.2021.08.010 · Cited by 37
“Major depressive disorder is a chronic and disabling condition, with about a third of the patients not responding to conventional pharmaceutical or cognitive-behavioral therapy [1].”
BackgroundHan, C., Wang, S., Kwak, K., Won, W.-Y., Lee, H.-Y., Chang, C., Tang, T. C., & Pae, C. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.04.020 · Cited by 41
Aikens, J., & Klinkman, M. (2012) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2012.01.004 · Cited by 38
“The primary STAR⁎D findings have previously been published [20].”
BackgroundKim, J., Stewart, R. J., Kang, H., Kim, J., Lee, H., Jhon, M., Lee, J., Kim, S., & Shin, I. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.002 · Cited by 42
The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
Gründer, G., & Jungaberle, H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1486-7386 · Cited by 45
“After unsuccessful depression treatment, about only one-quarter of patients reaches complete remission after switching to another antidepressant [16].”
BackgroundEvidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations
Möller, H., & Maier, W. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0070-9 · Cited by 39
“One of the reasons for this deficiency was that time restraints (continuation of previous treatment instead of switch) were not controlled for [46, 47, 127, 136, 138, 151, 152].”
BackgroundThe Eph receptor A4 plays a role in demyelination and depression-related behavior
Li, Y., Su, P., Chen, Y., Nie, J., Yuan, T., Wong, A. H. C., & Liu, F. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 36
Miller, M. D. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0005-6 · Cited by 40
“The sobering results of the Sequenced Treatment Alternatives to Relieve Depression trial show that no pharmacologic treatment can be expected to be effective in most patients and that strategies for improving the odds of a complete recovery, such as switching strategies, augmenting with a second drug, or adding psycho…”
BackgroundSIRT1 and SIRT2 Modulators: Potential Anti-Inflammatory Treatment for Depression?
Zhang, Y., Anoopkumar‐Dukie, S., & Davey, A. K. (2021) · Biomolecules · doi:10.3390/biom11030353 · Cited by 40
Revisiting the evolutionary origins of obesity: lazy versus peppy‐thrifty genotype hypothesis
Reddon, H., Patel, Y. S., Turcotte, M., Pigeyre, M., & Meyre, D. (2018) · Obesity Reviews · doi:10.1111/obr.12742 · Cited by 41
“This suggests that pleiotropic genes more often produce single multifunctional products (36).”
BackgroundPharmacologic management of adult depression.
Adams, S., Miller, K. E., & Zylstra, R. G. (2008) · PubMed · Cited by 42
Hyposalivation and Xerostomia and Burning Mouth Syndrome
Thakkar, J., & Lane, C. J. (2021) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2021.08.002 · Cited by 38
Antidepressant Combinations: Widely Used, but Far from Empirically Validated
Thase, M. E. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105600602 · Cited by 35
Self-citationBérard, A. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105600811 · Cited by 35
Eisendrath, S. J., Gillung, E., Delucchi, K., Mathalon, D. H., Yang, T. T., Satre, D. D., Rosser, R., Sipe, W. E. B., & Wolkowitz, O. M. (2015) · Mindfulness · doi:10.1007/s12671-014-0280-8 · Cited by 34
“Only 30% of individuals with MDD remit with one full trial of antidepressant medication, and remission rates for successive trials are even lower (Rush et al., 2006).”
BackgroundJha, M. K., Minhajuddin, A., Gadad, B. S., & Trivedi, M. H. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx060 · Cited by 34
“…of the Inventory of Depressive Symptomatology Clinician-rated (IDS-C) for 1 unit difference in log of PGDF in each treatment arm. treatment, over two-thirds of MDD patients continue to have significant depressive symptoms (Rush et al., 2006b, 200bc; Trivedi et al., 2006a, 2006b).”
MethodSelf-citationLin, C., Park, C., & McIntyre, R. S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.082 · Cited by 37
Hsu, C., Tseng, W., Wang, L., Yang, Y., Kao, H.-Y., & Lin, P. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.10.009 · Cited by 39
Association between Antidepressant Use during Pregnancy and Infants Born Small for Gestational Age
Ramos, É., St‐André, M., & Bérard, A. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005501000 · Cited by 35
Girlanda, F., Cipriani, A., Agrimi, E., Appino, M. G., Barichello, A., Beneduce, R., Bighelli, I., Bisoffi, G., Bisogno, A., Bortolaso, P., et al. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-731 · Cited by 33
Ricken, R., Wiethoff, K., Reinhold, T., Schietsch, K., Stamm, T. J., Kiermeir, J., Neu, P., Heinz, A., Bauer, M., & Adli, M. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.05.053 · Cited by 41
Chokshi, D. A., Avorn, J., & Kesselheim, A. S. (2010) · Health Affairs · doi:10.1377/hlthaff.2010.0843 · Cited by 35
Athreya, A. P., Brückl, T. M., Binder, E. B., Rush, A. J., Biernacka, J. M., Frye, M. A., Neavin, D. R., Skime, M. K., Monrad, D., Iyer, R. K., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00943-x · Cited by 34
Self-citationLong-Term Treatment of Depression with Antidepressants: A Systematic Narrative Review
Furukawa, T. A., Cipriani, A., Barbui, C., & Geddes, J. R. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/070674370705200902 · Cited by 33
“The STAR*D study directly informs this question because nonresponders to the open trial with citalopram (n = 727) were randomly allocated to sustained-release bupropion, sertraline, or extended-release venlafaxine.(21) The trial therefore compared a switch to an AD of the same class and a switch to a different class.”
MethodAn algorithm for the pharmacological treatment of depression
Spijker, J., & Nolen, W. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01492.x · Cited by 35
“Differences between the algorithms in the sequencing of steps and whether to switch or to augment after non-response to the first AD are not surprising because there is no evidence for a preferred sequential approach, as also demonstrated in STAR*D in which there were no statistically significant differences in effica…”
ResultWolitzky-Taylor, K. B., LeBeau, R. T., Arnaudova, I., Barnes‐Horowitz, N. M., Gong-Guy, E., Fears, S. C., Congdon, E. L., Freimer, N. B., & Craske, M. G. (2023) · JMIR Mental Health · doi:10.2196/46200 · Cited by 37
“Therapy was complemented by protocolized medication management as needed (modified from the STAR*D trial; [35]), delivered by psychiatry residents.”
MethodLefaucheur, J., Colzi, C., Hollander, E., Pampaloni, I., Ameringen, M. V., Baeken, C., Fusar‐Poli, P., Arango, C., Fontenelle, L. F., Batail, J.-M. V., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106140 · Cited by 33
Glucocorticoids as Predictors of Treatment Response in Depression
Horstmann, S., & Binder, E. B. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.586550 · Cited by 33
Bet, P. M., Hugtenburg, J. G., Penninx, B. W. J. H., van Balkom, A. J. L. M., Nolen, W. A., & Hoogendijk, W. J. G. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.06.023 · Cited by 33
“BAI scores were used to categorise anxiety disorders: mild (0-21), moderate (22-35) and severe disorder (36-63).”
STAR*D: A Tale and Trail of Bias
Pigott, H. E. (2011) · Ethical Human Psychology and Psychiatry · doi:10.1891/1559-4343.13.1.6 · Cited by 31
de Souza, L. H., Salum, G. A., Mosqueiro, B. P., Caldieraro, M. A., Guerra, T. A., & Fleck, M. P. D. A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.01.004 · Cited by 39
“The results, however, are still disappointing: approximately 20% of patients remit after a second antidepressant trial (Rush et al., 2006) and fewer than 20% remit after a third attempt (Fava et al., 2006).”
BackgroundKraus, C., Seiger, R., Pfabigan, D. M., Sladky, R., Tik, M., Paul, K., Woletz, M., Gryglewski, G., Vanicek, T., Komorowski, A., et al. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz030 · Cited by 32
Mazeh, D., Shahal, B., Aviv, A., Zemishlani, H., & Barak, Y. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32817396ae · Cited by 32
“Paroxetine was selected as the comparator drug because it is one of the most frequently prescribed selective seratonin reuptake inhibitors (SSRIs) worldwide (Nemeroff, 1993).”
BackgroundInfluentialUse of Treatment Algorithms for Depression
Trivedi, M. H., Fava, M., Marangell, L. B., Osser, D. N., & Shelton, R. C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0919 · Cited by 33
Self-citationKraus, C., Klöbl, M., Tik, M., Auer, B., Vanicek, T., Geissberger, N., Pfabigan, D. M., Hahn, A., Woletz, M., Paul, K., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-017-0009-x · Cited by 31
“After both sequential treatments in total about 30–60% achieve remission, leaving about 70–40% of all patients depressed [3, 4].”
BackgroundPredicting antidepressant response using early changes in cognition: A systematic review
Park, C., Pan, Z., Brietzke, E. M., Subramaniapillai, M., Rosenblat, J. D., Zuckerman, H., Lee, Y. L., Fus, D., & McIntyre, R. S. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.07.011 · Cited by 47
“According to the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, less than one third of patients achieve full remission of depressive symptoms from the first antidepressant trial [16,17], underscoring the need to improve antidepressant therapy and clinical outcomes in MDD.”
Deep brain stimulation for treatment-resistant depression: A psychiatric perspective
Giacobbe, P., & Kennedy, S. H. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0048-5 · Cited by 37
“A randomized approach to the treatment of major depressive disorder (MDD) recently has allowed a systematic examination of three sequential levels of treatment interventions, including switching within and among classes and combining antidepressant medications [29, 30 ].”
BackgroundPapakostas, G. I., Kornstein, S. G., Clayton, A. H., Soares, C. N., Hallett, L. A., Krishen, A., & Tucker, V. L. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32819f8400 · Cited by 35
“To our knowledge, only two other studies comparing bupropion with an SSRI were not included, and these studies were of special populations [i.e. citalopram-resistant depression (Rush et al., 2006) and bipolar depression (Post et al., 2006)].”
ResultPapakostas, G. I., Nielsen, R. Z., Dragheim, M., & Tonnoir, B. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.02.017 · Cited by 36
Switching antidepressants in the treatment of major depression: When, how and what to switch to?
Boyce, P. M., Hopwood, M., Morris, G., Hamilton, A., Bassett, D. L., Baune, B. T., Mulder, R., Porter, R., Parker, G. B., Singh, A., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.082 · Cited by 38
Treatment-Resistant Depression in Poland—Epidemiology and Treatment
Gałecki, P., Samochowiec, J., Mikułowska, M., & Szulc, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030480 · Cited by 38
“Over the last 60 years, several antidepressant drugs (ADs) have been developed that can be effective in treating MDD.”
ResultInfluential
Metadata
- Authors
- Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., Shores-Wilson, K., Niederehe, G., & Fava, M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- New York State Psychiatric Institute (US)
- Massachusetts General Hospital (US)
- National Institute of Mental Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-23
- Volume
- 354
- Issue
- 12
- Pages
- 1231-1242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140787893
- Cited by
- 1,033
- References
- 44
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 28 · 2021: 46 · 2020: 43 · 2019: 54 · 2018: 51 · 2017: 35 · 2016: 42 · 2015: 45 · 2014: 46 · 2013: 45 · 2012: 43
- FWCI
- 66.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, antidepressant switching, bupropion, sertraline, venlafaxine, treatment-resistant depression, symptom remission, antidepressant response, outpatients
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Female, Humans, Male, Remission Induction, Time Factors, Bupropion, Treatment Failure, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.